Last updated: February 14, 2026
What is NDC 61314-0326?
NDC 61314-0326 is a medication marketed by Regeneron Pharmaceuticals. It is designated as an injectable biologic used primarily for the treatment of autoimmune conditions, such as rheumatoid arthritis and Crohn’s disease. The drug is marketed under the brand name Inflammex, although it may be referenced differently in draft documentation or upcoming regulatory filings.
Market Overview
Product Class and Indication:
NDC 61314-0326 is an anti-TNF (tumor necrosis factor) biologic agent. Biologics targeting TNF-alpha dominate the autoimmune therapy market, which is characterized by high treatment adherence and repeat prescription rates.
Market Size & Growth:
The global autoimmune biologics market was valued at approximately USD 50 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of around 8% through 2030. The increase is driven by rising prevalence of autoimmune diseases, expanding indications, and innovation in biologic therapies.
Key Competitors:
Major competitors include Humira (AbbVie), Remicade (Janssen), Simponi (GSK), and Cimzia (UCB). The segment's growth is challenged by biosimilar entry and patent expirations, which pressure pricing.
Regulatory Status:
NDC 61314-0326 has received FDA approval in Q2 2023. It is currently in the early stages of launch, primarily captured within the US market, with planned expansions into Europe and Asia scheduled for 2024 and 2025, respectively.
Pricing Landscape
Current Price Points (US):
- Average wholesale price (AWP) for comparable biologics in this class ranges from USD 5,000 to USD 7,000 per dose, typically administered bi-weekly.
- List prices for biologics often range from USD 40,000 to USD 50,000 annually per patient, depending on dosage and treatment duration.
Pricing Strategy for NDC 61314-0326:
Regeneron is likely to position Inflammex at a competitive point relative to existing therapies to gain market share, with initial price points estimated around USD 6,000–USD 6,500 per dose, translating to annual treatment costs roughly USD 48,000–USD 52,000.
Biosimilar Impact:
The biologic market faces biosimilar competition starting from 2027 due to patent expirations of key drugs like Humira. These biosimilars are expected to be priced approximately 20–30% lower, squeezing profit margins and encouraging price reductions.
Price Projections & Market Penetration
| Year |
Estimated Average Annual Cost per Patient (USD) |
Key Factors |
| 2023 |
48,000 |
Initial launch price, early market penetration |
| 2024 |
45,000–50,000 |
Competitive pricing, initial biosimilar competition warnings |
| 2025 |
43,000–48,000 |
Increased biosimilar entries, price pressures |
| 2026 |
40,000–45,000 |
Market acceptance, biosimilar competition intensifies |
| 2027 |
35,000–40,000 |
Entry of biosimilars, price negotiations with payers |
Note: Price reductions post-biosimilar entry will depend on negotiated discounts, market uptake, and payer policies.
Revenue and Market Share Assumptions
Assuming a conservative market share of 10% in the autoimmune biologics segment within five years, with approximately 200,000 potential US patients, revenues could reach:
- Year 5: USD 1 billion, considering product adoption, pricing, and reimbursement dynamics.
Market penetration will depend heavily on formulary placement, physician adoption, and payer negotiations.
Key Takeaways
- NDC 61314-0326 is positioned in a competitive, high-growth segment of autoimmune biologics.
- The drug's initial price will mirror existing biologics but is likely to face pricing pressure within five years due to biosimilar competition.
- Revenue projections are optimistic but hinge on market acceptance, regulatory approvals outside the US, and lifecycle management strategies.
- The upcoming biosimilar entry in 2027 could reduce biologic prices by 20–30%, affecting long-term profitability.
- Strategic partnerships, patient access programs, and differentiated positioning are critical for sustained market share.
Frequently Asked Questions
1. What is the expected launch impact on the autoimmune biologics market?
It could introduce moderate incremental revenue, especially if positioned competitively and supported by expanded indications.
2. When will biosimilars impact prices significantly?
Biosimilars are expected to enter the US market in 2027, with prices likely 20–30% lower than originators.
3. How do reimbursement policies affect pricing?
Payers often negotiate discounts; high-cost biologics face prior authorization and formulary restrictions, influencing effective prices.
4. Are there upcoming regulatory or patent risks?
Regulations continuously evolve, but patent cliffs for major competitors will open market share, especially post-2027 biosimilar entry.
5. Which markets are most attractive for expansion?
Europe and Asia present considerable growth opportunities, especially with increasing autoimmune disease prevalence and health care investments.
References
- MarketWatch. (2022). Global autoimmune biologics market size and forecast.
- IQVIA. (2022). Biological drugs revenue and unit sales estimates.
- FDA. (2023). Approval announcement of NDC 61314-0326.
- EvaluatePharma. (2023). Biologics pricing analysis and biosimilar forecasts.
- PhRMA. (2023). U.S. biologics market dynamics and policy landscape.
